Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib 160 mg for advanced EGFR-positive NSCLC with non-driver co-mutations after slow/local progression on first-line Firmonertinib 80 mg
ChiCTR2500110343Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Progression-Free Survival by investigator per RECIST 1.1. Started Oct 2025; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500110343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110343.